NO301121B1 - Fremgangsmåte for fremstilling av et delesjonsmutantprotein med biologisk aktivitet til faktor VIII, DNA-sekvens, ekspresjonsvektor, samt transformert celle og avkom derav - Google Patents

Fremgangsmåte for fremstilling av et delesjonsmutantprotein med biologisk aktivitet til faktor VIII, DNA-sekvens, ekspresjonsvektor, samt transformert celle og avkom derav Download PDF

Info

Publication number: NO301121B1
Authority: NO; Norway
Prior art keywords: factor viii; amino acid; cell; deletion; acid sequence
Prior art date: 1987-06-12

Application number

NO890587A

Other languages

English (en)

Norwegian (no)

Other versions

NO890587L (no

NO890587D0 (no

Inventor

Albert Johannes Joseph V Ooyen

Hans Pannekoek

Martinus Philippus Verbeet

Robert Willem Van Leen

Original Assignee

Immuno Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-06-12

Filing date

1989-02-10

Publication date

1997-09-15

1989-02-10 Application filed by Immuno Ag filed Critical Immuno Ag

1989-02-10 Publication of NO890587L publication Critical patent/NO890587L/no

1989-02-10 Publication of NO890587D0 publication Critical patent/NO890587D0/no

1997-09-15 Publication of NO301121B1 publication Critical patent/NO301121B1/no

Links

108010054218 Factor VIII Proteins 0.000 title claims abstract description 144
102000001690 Factor VIII Human genes 0.000 title claims abstract description 143
229960000301 factor viii Drugs 0.000 title claims abstract description 133
238000000034 method Methods 0.000 title claims abstract description 29
238000012217 deletion Methods 0.000 title claims description 58
230000037430 deletion Effects 0.000 title claims description 58
239000013604 expression vector Substances 0.000 title claims description 34
108091028043 Nucleic acid sequence Proteins 0.000 title claims description 18
230000004071 biological effect Effects 0.000 title claims description 13
108010021466 Mutant Proteins Proteins 0.000 title claims description 10
102000008300 Mutant Proteins Human genes 0.000 title claims description 10
230000008569 process Effects 0.000 title claims description 5
238000002360 preparation method Methods 0.000 title abstract description 14
210000004027 cell Anatomy 0.000 claims description 87
108090000623 proteins and genes Proteins 0.000 claims description 68
102000004169 proteins and genes Human genes 0.000 claims description 35
125000003275 alpha amino acid group Chemical group 0.000 claims description 34
230000014509 gene expression Effects 0.000 claims description 34
238000013518 transcription Methods 0.000 claims description 19
230000035897 transcription Effects 0.000 claims description 19
150000001875 compounds Chemical class 0.000 claims description 18
230000001105 regulatory effect Effects 0.000 claims description 15
210000004962 mammalian cell Anatomy 0.000 claims description 12
210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 7
230000000977 initiatory effect Effects 0.000 claims description 7
108091026890 Coding region Proteins 0.000 claims description 6
238000013519 translation Methods 0.000 claims description 6
230000014616 translation Effects 0.000 claims description 6
230000014621 translational initiation Effects 0.000 claims description 6
238000002955 isolation Methods 0.000 claims description 5
OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 claims description 3
229940126214 compound 3 Drugs 0.000 claims description 3
238000003780 insertion Methods 0.000 claims description 3
230000037431 insertion Effects 0.000 claims description 3
235000015097 nutrients Nutrition 0.000 claims description 3
241000193830 Bacillus <bacterium> Species 0.000 claims description 2
210000001236 prokaryotic cell Anatomy 0.000 claims description 2
150000002500 ions Chemical class 0.000 claims 1
241000894007 species Species 0.000 claims 1
210000005253 yeast cell Anatomy 0.000 claims 1
239000012634 fragment Substances 0.000 abstract description 83
108090000765 processed proteins & peptides Proteins 0.000 abstract description 40
102000004196 processed proteins & peptides Human genes 0.000 abstract description 38
229920001184 polypeptide Polymers 0.000 abstract description 37
230000000694 effects Effects 0.000 abstract description 32
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract description 11
102100026735 Coagulation factor VIII Human genes 0.000 abstract description 9
201000003542 Factor VIII deficiency Diseases 0.000 abstract description 9
208000009292 Hemophilia A Diseases 0.000 abstract description 9
239000000203 mixture Substances 0.000 abstract description 5
239000013612 plasmid Substances 0.000 description 51
235000001014 amino acid Nutrition 0.000 description 31
229940024606 amino acid Drugs 0.000 description 29
150000001413 amino acids Chemical class 0.000 description 29
235000018102 proteins Nutrition 0.000 description 29
239000013598 vector Substances 0.000 description 25
239000002299 complementary DNA Substances 0.000 description 22
108020004414 DNA Proteins 0.000 description 21
238000002703 mutagenesis Methods 0.000 description 17
231100000350 mutagenesis Toxicity 0.000 description 17
108020004999 messenger RNA Proteins 0.000 description 13
238000010276 construction Methods 0.000 description 12
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 11
239000003636 conditioned culture medium Substances 0.000 description 11
210000004369 blood Anatomy 0.000 description 10
239000008280 blood Substances 0.000 description 10
230000009466 transformation Effects 0.000 description 10
125000005647 linker group Chemical group 0.000 description 9
238000001890 transfection Methods 0.000 description 9
238000003776 cleavage reaction Methods 0.000 description 8
210000002381 plasma Anatomy 0.000 description 8
108091008146 restriction endonucleases Proteins 0.000 description 8
230000007017 scission Effects 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 7
230000003321 amplification Effects 0.000 description 6
238000003556 assay Methods 0.000 description 6
239000000872 buffer Substances 0.000 description 6
230000013595 glycosylation Effects 0.000 description 6
239000003550 marker Substances 0.000 description 6
239000002609 medium Substances 0.000 description 6
238000003199 nucleic acid amplification method Methods 0.000 description 6
239000002773 nucleotide Substances 0.000 description 6
125000003729 nucleotide group Chemical group 0.000 description 6
230000010076 replication Effects 0.000 description 6
239000000523 sample Substances 0.000 description 6
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 5
238000002965 ELISA Methods 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
230000004927 fusion Effects 0.000 description 5
238000006206 glycosylation reaction Methods 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
108020004707 nucleic acids Proteins 0.000 description 5
102000039446 nucleic acids Human genes 0.000 description 5
150000007523 nucleic acids Chemical class 0.000 description 5
230000006337 proteolytic cleavage Effects 0.000 description 5
108020004705 Codon Proteins 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
108010000499 Thromboplastin Proteins 0.000 description 4
102000002262 Thromboplastin Human genes 0.000 description 4
241000700605 Viruses Species 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
238000010367 cloning Methods 0.000 description 4
230000015271 coagulation Effects 0.000 description 4
238000005345 coagulation Methods 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
230000002163 immunogen Effects 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
238000012423 maintenance Methods 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
241001515965 unidentified phage Species 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
241000701822 Bovine papillomavirus Species 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 3
101150074155 DHFR gene Proteins 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
108091081024 Start codon Proteins 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
229910000389 calcium phosphate Inorganic materials 0.000 description 3
235000011010 calcium phosphates Nutrition 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000013599 cloning vector Substances 0.000 description 3
230000009260 cross reactivity Effects 0.000 description 3
108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
230000035772 mutation Effects 0.000 description 3
230000008488 polyadenylation Effects 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000012360 testing method Methods 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
241000388186 Deltapapillomavirus 4 Species 0.000 description 2
241001524679 Escherichia virus M13 Species 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
108010005774 beta-Galactosidase Proteins 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
102000057593 human F8 Human genes 0.000 description 2
229960000900 human factor viii Drugs 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
230000010354 integration Effects 0.000 description 2
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
238000001466 metabolic labeling Methods 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
210000004897 n-terminal region Anatomy 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000004904 shortening Methods 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000005030 transcription termination Effects 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 2
MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 2
108010033683 von Willebrand factor drug combination factor VIII Proteins 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
101710117373 92 kDa protein Proteins 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
102000002110 C2 domains Human genes 0.000 description 1
108050009459 C2 domains Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102100023804 Coagulation factor VII Human genes 0.000 description 1
102100029117 Coagulation factor X Human genes 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
108010023321 Factor VII Proteins 0.000 description 1
108010061932 Factor VIIIa Proteins 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
229940123414 Folate antagonist Drugs 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
102100027612 Kallikrein-11 Human genes 0.000 description 1
241000235649 Kluyveromyces Species 0.000 description 1
FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
108010059881 Lactase Proteins 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
101100476480 Mus musculus S100a8 gene Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
101710116435 Outer membrane protein Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108010087702 Penicillinase Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
241000577979 Peromyscus spicilegus Species 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
241001197925 Theila Species 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
101710152431 Trypsin-like protease Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229940024546 aluminum hydroxide gel Drugs 0.000 description 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
-1 aminohexyl Chemical group 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
238000007820 coagulation assay Methods 0.000 description 1
229940105756 coagulation factor x Drugs 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000012937 correction Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
229940012413 factor vii Drugs 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000004052 folic acid antagonist Substances 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
229940116108 lactase Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229940079938 nitrocellulose Drugs 0.000 description 1
229950009506 penicillinase Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000867 polyelectrolyte Polymers 0.000 description 1
230000009465 prokaryotic expression Effects 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000013605 shuttle vector Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
239000004474 valine Substances 0.000 description 1
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
108010047303 von Willebrand Factor Proteins 0.000 description 1
102100036537 von Willebrand factor Human genes 0.000 description 1
229960001134 von willebrand factor Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Hematology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Immunology (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO890587A 1987-06-12 1989-02-10 Fremgangsmåte for fremstilling av et delesjonsmutantprotein med biologisk aktivitet til faktor VIII, DNA-sekvens, ekspresjonsvektor, samt transformert celle og avkom derav NO301121B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP87201121		1987-06-12
PCT/NL1988/000028 WO1988009813A1 (en)	1987-06-12	1988-06-13	Novel proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them

Publications (3)

Publication Number	Publication Date
NO890587L NO890587L (no)	1989-02-10
NO890587D0 NO890587D0 (no)	1989-02-10
NO301121B1 true NO301121B1 (no)	1997-09-15

Family

ID=8197627

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO890587A NO301121B1 (no)	1987-06-12	1989-02-10	Fremgangsmåte for fremstilling av et delesjonsmutantprotein med biologisk aktivitet til faktor VIII, DNA-sekvens, ekspresjonsvektor, samt transformert celle og avkom derav

Country Status (19)

Country	Link
US (2)	US5171844A (ko)
JP (1)	JP2771827B2 (ko)
KR (1)	KR970002915B1 (ko)
CN (1)	CN1033760C (ko)
AT (2)	ATE142691T1 (ko)
CA (1)	CA1341208C (ko)
DE (2)	DE3855523T2 (ko)
DK (1)	DK172631B1 (ko)
ES (2)	ES2169095T3 (ko)
FI (1)	FI103731B (ko)
GR (1)	GR3021545T3 (ko)
HU (2)	HU213300B (ko)
IE (1)	IE69026B1 (ko)
IL (1)	IL86693A (ko)
NO (1)	NO301121B1 (ko)
NZ (1)	NZ224992A (ko)
PT (1)	PT87721B (ko)
WO (1)	WO1988009813A1 (ko)
ZA (1)	ZA884216B (ko)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5595886A (en)	1986-01-27	1997-01-21	Chiron Corporation	Protein complexes having Factor VIII:C activity and production thereof
US5422260A (en) *	1986-05-29	1995-06-06	Genetics Institute, Inc. -Legal Affairs	Human factor VIII:c muteins
US6060447A (en) *	1987-05-19	2000-05-09	Chiron Corporation	Protein complexes having Factor VIII:C activity and production thereof
JPH0387173A (ja) *	1987-09-10	1991-04-11	Teijin Ltd	ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
FR2657884B1 (fr) *	1990-02-05	1994-09-02	Tm Innovation	Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
JPH06503710A (ja) *	1990-09-14	1994-04-28	カイロン　コーポレイション	酵母細胞におけるマクロファージ誘導タンパク質（ｍｉｐ）の発現
US20060122376A1 (en) *	1991-02-07	2006-06-08	Chiron Corporation	Protein complexes having factor VIII:C activity and production thereof
US5888974A (en) *	1992-04-07	1999-03-30	Emory University	Hybrid human/animal factor VIII
US5859204A (en) *	1992-04-07	1999-01-12	Emory University	Modified factor VIII
SE504074C2 (sv) *	1993-07-05	1996-11-04	Pharmacia Ab	Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5576291A (en) *	1993-09-13	1996-11-19	Baxter International Inc.	Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
AT403167B (de) *	1994-11-14	1997-11-25	Immuno Ag	Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US5641655A (en) *	1994-11-30	1997-06-24	Zymogenetics, Inc.	Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
AU5989796A (en) *	1995-06-06	1996-12-24	Board Of Regents Of The University Of Nebraska, by and on behalf of The University Of Nebraska Medical Center, The	Organ function replacement compositions and methods of makin g and using the same
US7560107B2 (en) *	1996-06-26	2009-07-14	Emory University	Modified factor VIII
AU735763B2 (en)	1997-12-05	2001-07-12	Immune Response Corporation, The	Novel vectors and genes exhibiting increased expression
US6221349B1 (en)	1998-10-20	2001-04-24	Avigen, Inc.	Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) *	1998-10-20	2001-03-13	Avigen, Inc.	Adeno-associated virus vectors for expression of factor VIII by target cells
US6358703B1 (en)	1998-12-10	2002-03-19	Bayer Corporation	Expression system for factor VIII
EP1325681A1 (en) *	2001-12-11	2003-07-09	Société des Produits Nestlé S.A.	Composition for promotion of bone growth and maintenance of bone health
WO2003100053A1 (en) *	2002-05-22	2003-12-04	The Children's Hospital Of Philadelphia	Compositions and methods for the treatment of hemophilia a
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
WO2005033321A2 (en)	2003-09-30	2005-04-14	The Trustees Of The University Of Pennsylvania	Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US7566701B2 (en)	2004-09-07	2009-07-28	Archemix Corp.	Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
CA2578046A1 (en)	2004-09-07	2006-03-16	Archemix Corp.	Aptamer medicinal chemistry
CA2579374A1 (en)	2004-09-07	2006-03-30	Archemix Corp.	Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
DK1824988T3 (en)	2004-11-12	2017-08-07	Bayer Healthcare Llc	LOCATION-SPECIFIC MODIFICATION OF FVIII
CN102994549B (zh)	2005-04-07	2015-02-11	宾夕法尼亚大学托管会	增强腺相关病毒载体功能的方法
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
US9359629B2 (en)	2007-12-27	2016-06-07	Baxalta Incorporated	Cell culture processes
JP5624891B2 (ja) *	2007-12-31	2014-11-12	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	ヒト血液凝固因子を発現するトランスジェニック非ヒト動物
DK3178835T3 (da)	2009-02-03	2019-06-24	Amunix Pharmaceuticals Inc	Forlængede rekombinante polypeptider og sammensætninger omfattende samme
US20110046060A1 (en)	2009-08-24	2011-02-24	Amunix Operating, Inc.,	Coagulation factor IX compositions and methods of making and using same
AU2010279463A1 (en)	2009-08-04	2012-03-01	Baxter Healthcare S.A.	Transgenic mouse knockout for FVIII and VWF - model of hemophilia A
JP5903048B2 (ja)	2009-12-06	2016-04-13	バイオジェンヘモフィリアインコーポレイテッド	第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法
US9315825B2 (en)	2010-03-29	2016-04-19	The Trustees Of The University Of Pennsylvania	Pharmacologically induced transgene ablation system
SG10201502270TA (en)	2010-03-29	2015-05-28	Univ Pennsylvania	Pharmacologically induced transgene ablation system
EP2591101B1 (en)	2010-07-09	2018-11-07	Bioverativ Therapeutics Inc.	Systems for factor viii processing and methods thereof
SG186875A1 (en)	2010-07-09	2013-02-28	Biogen Idec Hemophilia Inc	Chimeric clotting factors
CA2826316C (en)	2011-02-17	2021-04-27	The Trustees Of The University Of Pennsylvania	Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
EP3527218A1 (en)	2011-06-10	2019-08-21	Bioverativ Therapeutics Inc.	Pro-coagulant compounds and methods of use thereof
PT3513804T (pt)	2011-07-08	2022-06-02	Bioverativ Therapeutics Inc	Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos
US10656167B2 (en)	2011-07-25	2020-05-19	Bioverativ Therapeutics Inc.	Assays to monitor bleeding disorders
AU2012318292B2 (en)	2011-10-18	2015-08-20	Csl Limited	Method for improving the stability of purified Factor VIII after reconstitution
PL2804623T3 (pl)	2012-01-12	2020-03-31	Bioverativ Therapeutics Inc.	Chimeryczne polipeptydy czynnika viii i ich zastosowania
CA2863329C (en)	2012-01-12	2023-01-03	Biogen Idec Ma Inc.	Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
AU2013204636B2 (en)	2012-02-15	2016-04-14	Bioverativ Therapeutics Inc.	Recombinant Factor VIII proteins
BR112014020694A2 (pt)	2012-02-15	2018-05-08	Amunix Operating Inc.	proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CN104427995A (zh)	2012-06-08	2015-03-18	比奥根艾迪克Ma公司	嵌合凝血因子
CN104519897A (zh)	2012-06-08	2015-04-15	比奥根艾迪克Ma公司	促凝血化合物
EP3404105A1 (en)	2012-07-06	2018-11-21	Bioverativ Therapeutics Inc.	Cell line expressing single chain factor viii polypeptides and uses thereof
EA029685B1 (ru)	2012-07-11	2018-04-30	Амуникс Оперэйтинг Инк.	Комплекс фактора viii с xten и белком фактора фон виллебранда и его применение (варианты)
EP2877202A4 (en)	2012-07-25	2016-06-01	Biogen Ma Inc	BLOOD FACTOR MONITORING TEST AND USES THEREOF
AU2013331000B2 (en)	2012-10-18	2018-04-19	Bioverativ Therapeutics Inc.	Methods of using a fixed dose of a clotting factor
EP3943102A1 (en)	2012-10-30	2022-01-26	Bioverativ Therapeutics Inc.	Methods of using fviii polypeptide
HUE063051T2 (hu)	2013-02-15	2023-12-28	Bioverativ Therapeutics Inc	Optimalizált VIII. faktor gén
SG10201707600XA (en)	2013-03-15	2017-11-29	Biogen Ma Inc	Factor ix polypeptide formulations
TWI629993B (zh)	2013-03-15	2018-07-21	美商生物化學醫療公司	因子ｖｉｉｉ多肽調配物
US9719106B2 (en)	2013-04-29	2017-08-01	The Trustees Of The University Of Pennsylvania	Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
JP2016523919A (ja)	2013-06-28	2016-08-12	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用
EP3875106A1 (en)	2013-08-08	2021-09-08	Bioverativ Therapeutics Inc.	Purification of chimeric fviii molecules
TWI667255B (zh)	2013-08-14	2019-08-01	美商生物化學醫療公司	因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3065769A4 (en)	2013-11-08	2017-05-31	Biogen MA Inc.	Procoagulant fusion compound
EP4332839A3 (en)	2013-12-06	2024-06-05	Bioverativ Therapeutics Inc.	Population pharmacokinetics tools and uses thereof
RS63583B1 (sr)	2014-01-10	2022-10-31	Bioverativ Therapeutics Inc	Himerni proteini faktora viii i njihova upotreba
AU2015214245B2 (en)	2014-02-04	2020-09-10	Biogen Ma Inc.	Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CN105017410B (zh) *	2014-04-18	2018-06-08	北京诺思兰德生物技术股份有限公司	一种b区部分缺失型重组人凝血因子ⅷ
MA40864A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
EP3283126B1 (en)	2015-04-16	2019-11-06	Emory University	Recombinant promoters and vectors for protein expression in liver and use thereof
TWI741992B (zh)	2015-08-03	2021-10-11	美商百歐維拉提夫治療公司	因子ｉｘ融合蛋白以及其製備及使用方法
CN116479001A (zh)	2015-11-13	2023-07-25	武田药品工业株式会社	用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
EP3374388A1 (en)	2015-11-13	2018-09-19	Baxalta Incorporated	Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
BR112018015659A2 (pt)	2016-02-01	2018-12-26	Bioverativ Therapeutics Inc	genes otimizados do fator viii
CN109790529A (zh)	2016-06-24	2019-05-21	财团法人牧岩生命科学研究所	包含FVIII和vWF因子的嵌合蛋白及其用途
US20190381149A1 (en)	2016-12-02	2019-12-19	Bioverativ Therapeutics Inc.	Methods of treating hemophilic arthropathy using chimeric clotting factors
AU2017368328A1 (en)	2016-12-02	2019-07-18	Bioverativ Therapeutics Inc.	Methods of inducing immune tolerance to clotting factors
AU2018313921A1 (en)	2017-08-09	2020-03-12	Bioverativ Therapeutics Inc.	Nucleic acid molecules and uses thereof
KR101952102B1 (ko) *	2017-12-07	2019-02-26	주식회사 지앤피바이오사이언스	단백질 발현량이 증대된 인자 ⅷ 변이체 발현벡터
MX2020008152A (es)	2018-02-01	2020-11-24	Bioverativ Therapeutics Inc	Uso de vectores lentivirales que expresan el factor viii.
RU2020136050A (ru)	2018-04-04	2022-05-06	Сайджилон Терапьютикс, Инк.	Имплантируемые частицы и соответствующие способы
MX2020012397A (es)	2018-05-18	2021-04-12	Bioverativ Therapeutics Inc	Metodos de tratamiento de la hemofilia a.
TW202006141A (zh)	2018-07-16	2020-02-01	美商巴克斯歐塔公司	使用編碼具有增加表現的重組fviii變異體之病毒載體的a型血友病之基因療法
WO2020033863A1 (en)	2018-08-09	2020-02-13	Bioverativ Therapeutics Inc.	Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (es)	2018-09-27	2020-04-30	Sigilon Therapeutics Inc	Dispositivos implantables para terapia celular y métodos relacionados
IL284648B1 (en)	2019-01-16	2024-08-01	Baxalta Incorporated	Viral vectors encoding recombinant FVIII variants with enhanced expression for hemophilia A gene therapy
EP3736286A1 (en)	2019-05-09	2020-11-11	Biotest AG	Single chain factor viii molecule
US20220233650A1 (en)	2019-06-19	2022-07-28	Bioverativ Therapeutics Inc.	Recombinant factor viii-fc for treating hemophilia and low bone mineral density
WO2021119357A2 (en)	2019-12-12	2021-06-17	Baxalta Incorporated	Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
CA3188420A1 (en)	2020-08-07	2022-02-10	Joseph Bauman	Vesicle targeting proteins and uses of same
EP4355768A1 (en)	2021-06-14	2024-04-24	Takeda Pharmaceutical Company Limited	Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
AR126846A1 (es)	2021-08-23	2023-11-22	Bioverativ Therapeutics Inc	Genes del factor viii optimizados
CN118019758A (zh)	2021-09-30	2024-05-10	比奥维拉迪维治疗股份有限公司	编码免疫原性降低的因子viii多肽的核酸
WO2024081309A1 (en)	2022-10-11	2024-04-18	Sigilon Therapeutics, Inc.	Engineered cells and implantable elements for treatment of disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4886876A (en)	1983-03-31	1989-12-12	Scripps Clinic And Research Foundation	Factor VIII coagulant polypeptides
US4657894A (en)	1983-03-31	1987-04-14	Scripps Clinic & Research Foundation	New factor VIII coagulant polypeptides
US4857635A (en)	1983-03-31	1989-08-15	Scripps Clinic And Research Foundation	Factor VIII coagulant polypeptides and monoclonal antibodies tof them
US5004804A (en) *	1984-01-12	1991-04-02	Nordisk Gentofte	Method and composition for preparation of factor VIIIC
US4965199A (en) *	1984-04-20	1990-10-23	Genentech, Inc.	Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
IL74909A (en) *	1984-04-20	1992-01-15	Genentech Inc	Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
SE8501050D0 (sv)	1985-03-05	1985-03-05	Kabivitrum Ab	Biologically active fragments of human antihemophilic factor and method for preparation thereof
ES8801674A1 (es) *	1985-04-12	1988-02-16	Genetics Inst	Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
US4769336A (en)	1985-05-24	1988-09-06	Scripps Clinic And Research Foundation	Treatment of factor VIII inhibitors
KR910006424B1 (ko) *	1985-08-21	1991-08-24	인코텍스 비.브이	편성브리프(brief) 제조방법
FI98829C (fi) *	1986-01-27	1997-08-25	Chiron Corp	Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5595886A (en)	1986-01-27	1997-01-21	Chiron Corporation	Protein complexes having Factor VIII:C activity and production thereof
US5451521A (en)	1986-05-29	1995-09-19	Genetics Institute, Inc.	Procoagulant proteins
US5422260A (en)	1986-05-29	1995-06-06	Genetics Institute, Inc. -Legal Affairs	Human factor VIII:c muteins
EP0251843A1 (fr)	1986-06-06	1988-01-07	Transgene S.A.	Procédé de préparation de facteur VIII à partir de cellules de mammifères
US5543502A (en)	1986-06-24	1996-08-06	Novo Nordisk A/S	Process for producing a coagulation active complex of factor VIII fragments
IL83192A (en) *	1986-07-18	1992-11-15	Gist Brocades Nv	Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
IL84168A0 (en) *	1986-10-15	1988-03-31	Rorer Int Overseas	Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
US4980456A (en) *	1987-04-06	1990-12-25	Scripps Clinic And Research Foundation	Recombinant factor VIIIC derived fragments
FR2619314B1 (fr)	1987-08-11	1990-06-15	Transgene Sa	Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
JPH025890A (ja)	1988-06-24	1990-01-10	Chemo Sero Therapeut Res Inst	ニワトリのβ−アクチンプロモーターを用いたヒトファクター８Ｃの製造方法
SE465222C5 (sv)	1989-12-15	1998-02-10	Pharmacia & Upjohn Ab	Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning

1988
- 1988-06-10 IE IE175588A patent/IE69026B1/en not_active IP Right Cessation
- 1988-06-10 US US07/205,226 patent/US5171844A/en not_active Expired - Lifetime
- 1988-06-10 IL IL8669388A patent/IL86693A/en not_active IP Right Cessation
- 1988-06-11 CN CN88103482A patent/CN1033760C/zh not_active Expired - Fee Related
- 1988-06-13 CA CA000569359A patent/CA1341208C/en not_active Expired - Lifetime
- 1988-06-13 WO PCT/NL1988/000028 patent/WO1988009813A1/en active IP Right Grant
- 1988-06-13 DE DE3855523T patent/DE3855523T2/de not_active Expired - Fee Related
- 1988-06-13 AT AT88201209T patent/ATE142691T1/de not_active IP Right Cessation
- 1988-06-13 KR KR1019890700238A patent/KR970002915B1/ko not_active IP Right Cessation
- 1988-06-13 ES ES95110468T patent/ES2169095T3/es not_active Expired - Lifetime
- 1988-06-13 ZA ZA884216A patent/ZA884216B/xx unknown
- 1988-06-13 NZ NZ224992A patent/NZ224992A/xx unknown
- 1988-06-13 HU HU883818A patent/HU213300B/hu not_active IP Right Cessation
- 1988-06-13 DE DE3856505T patent/DE3856505T2/de not_active Expired - Fee Related
- 1988-06-13 JP JP63504632A patent/JP2771827B2/ja not_active Expired - Fee Related
- 1988-06-13 ES ES88201209T patent/ES2094111T3/es not_active Expired - Lifetime
- 1988-06-13 AT AT95110468T patent/ATE209679T1/de not_active IP Right Cessation
- 1988-06-14 PT PT87721A patent/PT87721B/pt not_active IP Right Cessation
1989
- 1989-02-09 DK DK198900587A patent/DK172631B1/da not_active IP Right Cessation
- 1989-02-10 FI FI890643A patent/FI103731B/fi not_active IP Right Cessation
- 1989-02-10 NO NO890587A patent/NO301121B1/no not_active IP Right Cessation
1995
- 1995-04-03 US US08/416,532 patent/US6316226B1/en not_active Expired - Lifetime
- 1995-07-04 HU HU95P/P00758P patent/HU211503A9/hu unknown
1996
- 1996-11-06 GR GR960402919T patent/GR3021545T3/el unknown

Also Published As

Publication number	Publication date
FI890643A (fi)	1989-02-10
ATE142691T1 (de)	1996-09-15
JPH02500484A (ja)	1990-02-22
US6316226B1 (en)	2001-11-13
DE3855523T2 (de)	1997-02-06
WO1988009813A1 (en)	1988-12-15
CA1341208C (en)	2001-03-27
IE69026B1 (en)	1996-08-07
DK58789D0 (da)	1989-02-09
DE3855523D1 (de)	1996-10-17
CN1033760C (zh)	1997-01-08
IL86693A (en)	1994-06-24
DK58789A (da)	1989-02-09
NO890587L (no)	1989-02-10
NO890587D0 (no)	1989-02-10
IL86693A0 (en)	1988-11-30
DK172631B1 (da)	1999-03-22
FI103731B1 (fi)	1999-08-31
HU213300B (en)	1997-05-28
KR890701739A (ko)	1989-12-21
ATE209679T1 (de)	2001-12-15
IE881755L (en)	1988-12-12
DE3856505D1 (de)	2002-01-10
ZA884216B (en)	1989-02-22
KR970002915B1 (ko)	1997-03-12
PT87721A (pt)	1988-07-01
NZ224992A (en)	1991-07-26
CN1030609A (zh)	1989-01-25
JP2771827B2 (ja)	1998-07-02
FI103731B (fi)	1999-08-31
ES2169095T3 (es)	2002-07-01
GR3021545T3 (en)	1997-02-28
ES2094111T3 (es)	1997-01-16
FI890643A0 (fi)	1989-02-10
US5171844A (en)	1992-12-15
DE3856505T2 (de)	2002-08-08
HU211503A9 (en)	1995-11-28
PT87721B (pt)	1992-10-30

Legal Events

Date	Code	Title	Description
2006-01-30	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO301121B1 (no)	1997-09-15	Fremgangsmåte for fremstilling av et delesjonsmutantprotein med biologisk aktivitet til faktor VIII, DNA-sekvens, ekspresjonsvektor, samt transformert celle og avkom derav
US6346513B1 (en)	2002-02-12	Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0294910B1 (en)	1996-09-11	Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
FI98829C (fi)	1997-08-25	Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5595886A (en)	1997-01-21	Protein complexes having Factor VIII:C activity and production thereof
EP0506757B2 (en)	2005-10-26	A recombinant human factor viii derivative
US5422260A (en)	1995-06-06	Human factor VIII:c muteins
EP0253455A1 (en)	1988-01-20	Method for the preparation of proteins with factor VIII activity by microbial host cells; expression vectors, host cells, antibodies
JP2771129B2 (ja)	1998-07-02	第ｖｉｉｉ：ｃ因子活性を有するタンパク質複合体およびその製法
JP2000511407A (ja)	2000-09-05	不活性化耐性第▲ｖｉｉｉ▼因子
US20060122376A1 (en)	2006-06-08	Protein complexes having factor VIII:C activity and production thereof
AU606925B2 (en)	1991-02-21	A method for producing factor viii in high yield
AU627150B2 (en)	1992-08-20	Novel proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
WO1992006999A1 (en)	1992-04-30	Therapeutic fragments of von willebrand factor